One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...

A single infusion of a CRISPR-based gene therapy eliminated painful crises in 27 of 28 patients with severe sickle cell ...

FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...

There's more to young biopharma companies than their numbers, but those numbers are still an important part of each ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...

A 23-year-old man from Louisiana has become one of the first people in the United States to be functionally cured of sickle ...

Next-generation cell therapies are reshaping therapeutics by precisely engineering living cells for both ex vivo and in vivo applications. Cutting-edge tools—including Cas enzymes (Cas9, Cas12a), base ...

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...